BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, July 7, 2026
See today's BioWorld
Home » Sotio opens lab in Beijing to treat prostate, lung cancer patients
To read the full story, subscribe or sign in.

Sotio opens lab in Beijing to treat prostate, lung cancer patients

Aug. 7, 2014
By Shannon Ellis
SHANGHAI – Sotio AS, of Prague, has expanded its China footprint with the opening of a GMP, clean-room lab for the production of active cellular immunotherapy treatments against cancer diseases. This is their second facility, giving them a combined lab space of 1,000 square meters in Beijing. Sotio will produce therapeutic cellular treatments for patients with prostate and lung cancer.
BioWorld

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 6, 2026.
  • CINP 2026: Prenatal and adolescent stress shape brain vulnerability

    BioWorld Science
    Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
  • Ontrack Therapeutics divulges compounds for neurodegenerative diseases

    BioWorld Science
    Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
  • IPO puzzle pieces

    Neuracle eyes Shanghai IPO as global BCI funding surges

    BioWorld
    Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
  • Illustration of brain and brain waves, concept of focal seizure

    Hyperexcitability may be joint problem in epilepsy, dementia

    BioWorld
    The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing